Global DNA/RNA Quality Control 麻豆原创 Research Report 2024

Publication ID:

PB511246260

Publication Date:

November 8, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

DNA/RNA Quality Control (QC) is the process of assessing the quality, integrity, and concentration of nucleic acid samples (DNA or RNA) to ensure they are suitable for downstream applications such as sequencing, PCR, or gene expression analysis. High-quality nucleic acid samples are critical for reliable and accurate results in molecular biology and clinical diagnostics.
The global DNA/RNA Quality Control market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for DNA/RNA Quality Control is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for DNA/RNA Quality Control is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for DNA/RNA Quality Control in Biological Research is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of DNA/RNA Quality Control include QIMA Life Sciences, Thermo Fisher Scientific, QIAGEN, PathoQuest, Genomics, Cambridge Genomic Services, Eurofins Genomics, Creative Biogene, Norgen Biotek, Life Magnetics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for DNA/RNA Quality Control, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding DNA/RNA Quality Control.
The DNA/RNA Quality Control market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global DNA/RNA Quality Control market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the DNA/RNA Quality Control companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
QIMA Life Sciences
Thermo Fisher Scientific
QIAGEN
PathoQuest
Genomics
Cambridge Genomic Services
Eurofins Genomics
Creative Biogene
Norgen Biotek
Life Magnetics
BigOmics Analytics
LC Sciences
Omega Bioservices
Hokkaido System Science
Segment by Type
DNA Quality Control
RNA Quality Control
Segment by Application
Biological Research
Medical Diagnostics
Genomics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of DNA/RNA Quality Control company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global DNA/RNA Quality Control 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 DNA Quality Control
1.2.3 RNA Quality Control
1.3 麻豆原创 by Application
1.3.1 Global DNA/RNA Quality Control 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biological Research
1.3.3 Medical Diagnostics
1.3.4 Genomics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global DNA/RNA Quality Control 麻豆原创 Perspective (2019-2030)
2.2 Global DNA/RNA Quality Control Growth Trends by Region
2.2.1 Global DNA/RNA Quality Control 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 DNA/RNA Quality Control Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 DNA/RNA Quality Control Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 DNA/RNA Quality Control 麻豆原创 Dynamics
2.3.1 DNA/RNA Quality Control Industry Trends
2.3.2 DNA/RNA Quality Control 麻豆原创 Drivers
2.3.3 DNA/RNA Quality Control 麻豆原创 Challenges
2.3.4 DNA/RNA Quality Control 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top DNA/RNA Quality Control Players by Revenue
3.1.1 Global Top DNA/RNA Quality Control Players by Revenue (2019-2024)
3.1.2 Global DNA/RNA Quality Control Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global DNA/RNA Quality Control 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by DNA/RNA Quality Control Revenue
3.4 Global DNA/RNA Quality Control 麻豆原创 Concentration Ratio
3.4.1 Global DNA/RNA Quality Control 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by DNA/RNA Quality Control Revenue in 2023
3.5 Global Key Players of DNA/RNA Quality Control Head office and Area Served
3.6 Global Key Players of DNA/RNA Quality Control, Product and Application
3.7 Global Key Players of DNA/RNA Quality Control, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 DNA/RNA Quality Control Breakdown Data by Type
4.1 Global DNA/RNA Quality Control Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global DNA/RNA Quality Control Forecasted 麻豆原创 Size by Type (2025-2030)
5 DNA/RNA Quality Control Breakdown Data by Application
5.1 Global DNA/RNA Quality Control Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global DNA/RNA Quality Control Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America DNA/RNA Quality Control 麻豆原创 Size (2019-2030)
6.2 North America DNA/RNA Quality Control 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America DNA/RNA Quality Control 麻豆原创 Size by Country (2019-2024)
6.4 North America DNA/RNA Quality Control 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe DNA/RNA Quality Control 麻豆原创 Size (2019-2030)
7.2 Europe DNA/RNA Quality Control 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe DNA/RNA Quality Control 麻豆原创 Size by Country (2019-2024)
7.4 Europe DNA/RNA Quality Control 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific DNA/RNA Quality Control 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific DNA/RNA Quality Control 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific DNA/RNA Quality Control 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific DNA/RNA Quality Control 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America DNA/RNA Quality Control 麻豆原创 Size (2019-2030)
9.2 Latin America DNA/RNA Quality Control 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America DNA/RNA Quality Control 麻豆原创 Size by Country (2019-2024)
9.4 Latin America DNA/RNA Quality Control 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa DNA/RNA Quality Control 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa DNA/RNA Quality Control 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa DNA/RNA Quality Control 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa DNA/RNA Quality Control 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 QIMA Life Sciences
11.1.1 QIMA Life Sciences Company Details
11.1.2 QIMA Life Sciences Business Overview
11.1.3 QIMA Life Sciences DNA/RNA Quality Control Introduction
11.1.4 QIMA Life Sciences Revenue in DNA/RNA Quality Control Business (2019-2024)
11.1.5 QIMA Life Sciences Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Details
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific DNA/RNA Quality Control Introduction
11.2.4 Thermo Fisher Scientific Revenue in DNA/RNA Quality Control Business (2019-2024)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 QIAGEN
11.3.1 QIAGEN Company Details
11.3.2 QIAGEN Business Overview
11.3.3 QIAGEN DNA/RNA Quality Control Introduction
11.3.4 QIAGEN Revenue in DNA/RNA Quality Control Business (2019-2024)
11.3.5 QIAGEN Recent Development
11.4 PathoQuest
11.4.1 PathoQuest Company Details
11.4.2 PathoQuest Business Overview
11.4.3 PathoQuest DNA/RNA Quality Control Introduction
11.4.4 PathoQuest Revenue in DNA/RNA Quality Control Business (2019-2024)
11.4.5 PathoQuest Recent Development
11.5 Genomics
11.5.1 Genomics Company Details
11.5.2 Genomics Business Overview
11.5.3 Genomics DNA/RNA Quality Control Introduction
11.5.4 Genomics Revenue in DNA/RNA Quality Control Business (2019-2024)
11.5.5 Genomics Recent Development
11.6 Cambridge Genomic Services
11.6.1 Cambridge Genomic Services Company Details
11.6.2 Cambridge Genomic Services Business Overview
11.6.3 Cambridge Genomic Services DNA/RNA Quality Control Introduction
11.6.4 Cambridge Genomic Services Revenue in DNA/RNA Quality Control Business (2019-2024)
11.6.5 Cambridge Genomic Services Recent Development
11.7 Eurofins Genomics
11.7.1 Eurofins Genomics Company Details
11.7.2 Eurofins Genomics Business Overview
11.7.3 Eurofins Genomics DNA/RNA Quality Control Introduction
11.7.4 Eurofins Genomics Revenue in DNA/RNA Quality Control Business (2019-2024)
11.7.5 Eurofins Genomics Recent Development
11.8 Creative Biogene
11.8.1 Creative Biogene Company Details
11.8.2 Creative Biogene Business Overview
11.8.3 Creative Biogene DNA/RNA Quality Control Introduction
11.8.4 Creative Biogene Revenue in DNA/RNA Quality Control Business (2019-2024)
11.8.5 Creative Biogene Recent Development
11.9 Norgen Biotek
11.9.1 Norgen Biotek Company Details
11.9.2 Norgen Biotek Business Overview
11.9.3 Norgen Biotek DNA/RNA Quality Control Introduction
11.9.4 Norgen Biotek Revenue in DNA/RNA Quality Control Business (2019-2024)
11.9.5 Norgen Biotek Recent Development
11.10 Life Magnetics
11.10.1 Life Magnetics Company Details
11.10.2 Life Magnetics Business Overview
11.10.3 Life Magnetics DNA/RNA Quality Control Introduction
11.10.4 Life Magnetics Revenue in DNA/RNA Quality Control Business (2019-2024)
11.10.5 Life Magnetics Recent Development
11.11 BigOmics Analytics
11.11.1 BigOmics Analytics Company Details
11.11.2 BigOmics Analytics Business Overview
11.11.3 BigOmics Analytics DNA/RNA Quality Control Introduction
11.11.4 BigOmics Analytics Revenue in DNA/RNA Quality Control Business (2019-2024)
11.11.5 BigOmics Analytics Recent Development
11.12 LC Sciences
11.12.1 LC Sciences Company Details
11.12.2 LC Sciences Business Overview
11.12.3 LC Sciences DNA/RNA Quality Control Introduction
11.12.4 LC Sciences Revenue in DNA/RNA Quality Control Business (2019-2024)
11.12.5 LC Sciences Recent Development
11.13 Omega Bioservices
11.13.1 Omega Bioservices Company Details
11.13.2 Omega Bioservices Business Overview
11.13.3 Omega Bioservices DNA/RNA Quality Control Introduction
11.13.4 Omega Bioservices Revenue in DNA/RNA Quality Control Business (2019-2024)
11.13.5 Omega Bioservices Recent Development
11.14 Hokkaido System Science
11.14.1 Hokkaido System Science Company Details
11.14.2 Hokkaido System Science Business Overview
11.14.3 Hokkaido System Science DNA/RNA Quality Control Introduction
11.14.4 Hokkaido System Science Revenue in DNA/RNA Quality Control Business (2019-2024)
11.14.5 Hokkaido System Science Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

QIMA Life Sciences
Thermo Fisher Scientific
QIAGEN
PathoQuest
Genomics
Cambridge Genomic Services
Eurofins Genomics
Creative Biogene
Norgen Biotek
Life Magnetics
BigOmics Analytics
LC Sciences
Omega Bioservices
Hokkaido System Science

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.